Document:

EX-10.16

 Exhibit 10.16 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***] 

HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE 

COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. 

FIRST AMENDMENT TO DEVELOPMENT, MANUFACTURING AND

 SUPPLY AGREEMENT 

THIS FIRST AMENDMENT TO DEVELOPMENT, MANUFACTURING
AND SUPPLY AGREEMENT (this “Amendment”) is made and entered into as of October 19, 2016 by and between Alkermes Pharma Ireland Limited, a private limited company organized and
existing under the laws of the Republic of Ireland (“Alkermes”), and Recro Pharma, Inc., a corporation organized and existing under the laws of Pennsylvania (“Recro”), Recro and Alkermes are sometimes hereinafter
referred to each as a “Party” and collectively as the “Parties.” 
 RECITALS:

 WHEREAS, Alkermes and Recro entered into that certain Development, Manufacturing and Supply Agreement on July 10, 2015 (the
“Agreement”); 
 WHEREAS, in connection with Alkermes’ manufacturing and supply of BC Parenteral Meloxicam pursuant to
the Agreement, the Parties are contemplating constructing a Manufacturing Suite (as defined below); 
 WHEREAS, the Parties desire to amend
the terms of the Agreement as set forth herein to provide for the allocation of costs and expenses related to a portion of the design of the Manufacturing Suite; and WHEREAS, in the event the Parties agree to progress with further design and
construction of the Manufacturing Suite the Parties shall further amend the terms of the Agreement to provide for the allocation of costs and expenses related to such further design and construction. 

AGREEMENT: 

Now, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Alkermes and Recro agree as
follows: 
 Article 1 

Definitions 

1.1    All capitalized terms used but not otherwise defined herein shall have the meaning ascribed thereto in the
Agreement. 
 Article 2 

Amendments to Agreement 

2.1    Article 5 of the Agreement is hereby amended by adding the following new Section 5.8: 

“5.8 Manufacturing Suite. Notwithstanding any other provision in this Agreement: The Parties are designing a manufacturing suite
and related equipment at the Alkermes Facility for the manufacture 

  
 1 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***] 

HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE 

COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. 
  

 
and supply of BC Parenteral Meloxicam under the terms of this Agreement (the “Manufacturing Suite”). From the date of this Amendment until December 16, 2016, when Recro shall
notify Alkermes as to whether Recro wishes to enter into an additional amendment to the Agreement in respect of further design and construction of the Manufacturing Suite and allocation of costs and expenses related to same (the “Second
Amendment”), it is hereby agreed that Alkermes shall procure basis of design services in respect of the Manufacturing Suite (the “Basis of Design Services”). In the event Recro notifies Alkermes, in accordance with this
Amendment, that Recro wishes to enter into the Second Amendment, Alkermes shall continue to procure the Basis of Design Services up to the Basis of Design Cost (as hereinafter defined). In the event Recro notifies Alkermes, in accordance with this
Amendment, that Recro does not wish to enter into the Second Amendment Alkermes shall cease procurement of the Basis of Design Services. In either of the aforementioned events, Recro agrees to pay for [***]% of the costs of the Basis of Design
Services in a total amount not to exceed $[***], unless otherwise agreed by the Parties in writing (to include e-mail) (the “Basis of Design Cost”). [***]. Alkermes shall grant Recro a credit
in respect of an agreed portion of the Basis of Design Cost against Recro’s future capital obligations related to the further design and construction of the Manufacturing Suite only. 

General 

2.2    No Other Amendments. Except as expressly set forth in this Amendment, this Amendment shall not, by
implication or otherwise, limit, impair, constitute a waiver of or otherwise affect any rights or remedies of either Party under the Agreement, or alter, modify, amend or in any way affect any of the other terms, obligations or covenants contained
in the Agreement, all of which shall continue in full force and effect. 
 2.3    Miscellaneous
Provisions. This Amendment shall be subject to the miscellaneous provisions contained in Article 13 of the Agreement, which are incorporated by reference herein, in each case, mantis mutandi. 

[Remainder of this Page Intentionally Left Blank] 

  
 2 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***] 

HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE 

COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. 
  

 IN WITNESS WHEREOF, the Parties have caused this Amendment to be executed by their respective duly authorized
representatives as of the date set forth above. 
  

			
	ALKERMES PHARMA IRELAND LIMITED

 
			
		
	By:	 	 /s/ Richie Paul

		 	(Signature)

 
			
		
	Name:	 	 Richie Paul

 
			
		
	Title:	 	 Director

 
			
	
	RECRO PHARMA, INC.

 
			
		
	By:	 	 /s/ Gerri Henwood

		 	(Signature)

 
			
		
	Name:	 	 Gerri Henwood

 
			
		
	Title:	 	 CEO

 [Signature Page to First Amendment to Development, Manufacturing and Supply Agreement]EX-10.17

 Exhibit 10.17 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***] 

HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE 

COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. 

SECOND AMENDMENT TO DEVELOPMENT, MANUFACTURING AND

 SUPPLY AGREEMENT 

THIS SECOND AMENDMENT TO DEVELOPMENT,
MANUFACTURING AND SUPPLY AGREEMENT (this “Second Amendment”) is made and entered into as of February 1, 2017 by and between Alkermes Pharma Ireland
Limited, a private limited company organized and existing under the laws of the Republic of Ireland (“Alkermes”), and Recro Pharma, Inc., a corporation organized and existing under the laws of Pennsylvania
(“Recro”). Recro and Alkermes are sometimes hereinafter referred to each as a “Party” and collectively as the “Parties.” 

RECITALS: 

WHEREAS, Alkermes and Recro entered into that certain Development, Manufacturing and Supply Agreement on July 10, 2015 , as amended by
that certain First Amendment to the Development, Manufacturing and Supply Agreement between Alkermes and Recro dated as of October 19, 2016 (the “Agreement”); 

WHEREAS, in connection with Alkermes’ manufacture and supply of BC Parenteral Meloxicam pursuant to the Agreement, the Parties are
designing a Manufacturing Suite (as defined below); 
 WHEREAS, pursuant to that certain First Amendment to Development, Manufacturing and
Supply Agreement between Alkermes and Recro dated as of October 19, 2016 (the “First Amendment”), it was agreed that Alkermes would procure Basis of Design Services (as defined below) and that Recro would notify Alkermes as to
whether Recro wishes to enter into an additional amendment to the Agreement in respect of further design and construction of the Manufacturing Suite and the allocation of costs and expenses related to same; and 

WHEREAS, the Parties have agreed to progress with further design of the Manufacturing Suite and desire to further amend the terms of the
Agreement to provide for the allocation of costs and expenses related to such Detailed Design Services (as defined below). 

AGREEMENT: 

Now, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Alkermes and Recro
agree as follows: 
 Article 1 

Definitions 

1.1    All capitalized terms used but not otherwise defined herein shall have the meaning ascribed thereto in the
Agreement. 

  
 1 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***] 

HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE 

COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. 
  

 Article 2 

Amendments to Agreement 

2.1    Article 5 of the Agreement is hereby amended by the deletion of the current Section 5.8 and its
replacement by the following: 
 “5.8    Manufacturing Suite. Notwithstanding any other provision in
this Agreement: 
 The Parties are designing a manufacturing suite and related equipment at the Alkermes Facility for the manufacture and
supply of BC Parenteral Meloxicam (the “Manufacturing Suite”). Alkermes shall procure and render concept and basis of design services in respect of the Manufacturing Suite (the “Basis of Design Services”) on the
basis that Recro agrees to pay for [***]% of the costs of the Basis of Design Services in a total amount not to exceed $[***], unless otherwise agreed by the Parties in writing (to include e-mail) (the
“Basis of Design Cost”). 
 Alkermes shall procure and render the further design of the Manufacturing Suite (the
“Detailed Design Services”), provided always that Recro shall be entitled, at any time prior to the completion of the Detailed Design Services, to require the Detailed Design Services to be ceased by delivering a written notice to
Alkermes (a “Detailed Design Cessation Notice”) which shall take effect on the business day following the date of receipt by Alkermes of the Detailed Design Cessation Notice (the “Detailed Design Cessation Effective
Date”), on the condition that Recro shall pay [***]% of all costs and liabilities incurred by Alkermes in respect of the Detailed Design Services, whether such costs or liabilities are incurred on or prior to the Detailed Design Cessation
Effective Date or, in respect of any agreement entered into by Alkermes for the purposes of procuring the Detailed Design Services, are incurred after the Detailed Design Cessation Effective Date in connection with the termination by Alkermes of
such agreement in accordance with its terms (the “Detailed Design Cessation Costs”); provided, that Alkermes shall provide a notice of termination of any such agreement on the Detailed Design Cessation Effective Date;
provided further, that the Detailed Design Cessation Costs shall not exceed the Detailed Design Cost (as defined below). 
 Where the
Detailed Design Services are completed without the delivery by Recro of a Detailed Design Cessation Notice, Recro agrees to pay for [***]% of the costs of the Detailed Design Services in a total amount not to exceed $[***], unless otherwise agreed
by the Parties in writing (to include e-mail) (the “Detailed Design Cost”). 

  
 2 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***] 

HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE 

COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. 
  

 [***]. For the Basis of Design Cost and the Detailed Design Cost, together with each such
invoice Alkermes will provide Recro with a breakdown of how much of the costs in such invoice relate to facility costs and how much relate to capital equipment, together with supporting documentation. Alkermes shall grant Recro, in accordance with
said breakdown, a credit in respect of the portion of the Basis of Design Cost and the Detailed Design Cost allocated to facility costs against Recro’s future obligations related to the purchase of equipment for the Manufacturing Suite. 

On or before February 10, 2017, Recro and Alkermes shall enter into a further amendment to the Agreement in respect of, inter alia,
construction of, procurement related to, and verification of the Manufacturing Suite and allocation of costs and expenses related to same. 

For the avoidance of doubt and notwithstanding anything else contained in this Agreement, it is acknowledged and agreed that neither the Basis
of Design Services nor the Detailed Design Services constitute Services (as defined in Section 1.84 of this Agreement) for the purposes of this Agreement.” 

Article 3 
 General

 3.1    No Other Amendments. Except as expressly set forth in this Second Amendment, this Second
Amendment shall not, by implication or otherwise, limit, impair, constitute a waiver of or otherwise affect any rights or remedies of either Party under the Agreement, or alter, modify, amend or in any way affect any of the other terms, obligations
or covenants contained in the Agreement, all of which shall continue in full force and effect. 

3.2    Miscellaneous Provisions. This Second Amendment shall be subject to the miscellaneous provisions
contained in Article 13 of the Agreement, which are incorporated by reference herein, in each case, mutatis mutandi. 
 [Remainder
of this Page Intentionally Left Blank] 

  
 3 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***] 

HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE 

COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. 
  

 IN WITNESS WHEREOF, the Parties have caused this Second Amendment to be executed by their respective duly
authorized representatives as of the date set forth above. 
  

			
	ALKERMES PHARMA IRELAND LIMITED

 
			
		
	By:	 	 /s/ Shane Cooke

	(Signature)

 
			
		
	Name:	 	 Shane Cooke

 
			
		
	Title:	 	 Director

 
			
	
	RECRO PHARMA, INC.

 
			
		
	By:	 	 /s/ Michael Celano

	(Signature)

 
			
		
	Name:	 	 Michael Celano

 

			
		
	Title:	 	 CFO

 [Signature Page to Second Amendment to Development, Manufacturing and Supply Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}]]